Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05293665
Other study ID # UB-612-305
Secondary ID U1111-1276-95282
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date March 16, 2022
Est. completion date September 2023

Study information

Verified date October 2022
Source Vaxxinity, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, international, randomized, active-controlled platform study with each sub-study designed to randomize subjects to receive a single injection with UB-612 or a comparator COVID-19 vaccine in 1:1 ratio.


Description:

The current platform protocol is designed to determine the safety and immunizing activity of a booster dose of 100 μg UB-612 in patients who have received a different vaccine 3 months or more before the study start (i.e., Day 1). The randomized, active-controlled multicenter study sponsored by Vaxxinity will be conducted in several countries under a master platform protocol outlining common objectives, endpoints, population, study design, and data analysis. The platform protocol is designed for multiple sub-studies to be implemented at any time, each independently addressing the same set of scientific questions aimed to evaluate the immune responses after a booster injection with UB-612 vaccine candidate and a particular comparator COVID-19 vaccine product.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 944
Est. completion date September 2023
Est. primary completion date November 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: 1. Signed and dated informed consent/assent after reading the consent/assent form and having adequate opportunity to discuss the study with an investigator or designee. 2. Documented fully vaccinated with primary series of a comparator vaccine. Primary immunization is defined as 2 doses spaced approximately 3-16 weeks apart. The last dose of the previous vaccine must have been administered at least three (3) months (Pfizer at least (5) months) prior to Day 1, taking into consideration the current local and national regulations, and according to details related to individual comparators provided in relevant sub-studies. Documentation, such as the National Health Service (NHS) COVID Pass, United States Centers for Disease Control vaccine card, or equivalent documentation (e.g., medical records, vaccine passport; in accordance with local approved vaccination record documentation) will be required for proof of vaccination, vaccine manufacturer and vaccination dates. 3. No clinically significant health problems that could affect the safety of the subject, as determined by the investigator by medical history, laboratory tests and physical examination. May have a stable pre-existing medical condition that did not require significant change in medication or hospitalization in 3 months before screening or which, in the judgement of the investigator is unlikely to require a significant change in therapy or hospitalization for worsening disease in the 3 months after Day 1. 4. Negative SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) or antigen test within 24-48 hours prior to receipt of injections on Day 1. 5. Female subjects of non-childbearing potential may be enrolled. 6. Males and WOCBP, 16 years or older, may be enrolled in the study if they are willing to practice abstinence from sexual intercourse or are willing to use acceptable methods of contraception as described below, from the time of signing the informed consent/assent during the screening period through study product injection on Day 1 and until completion of Day 29. Acceptable methods of contraception should be consistent with local availability/regulations regarding the use of contraceptive methods for those participating in clinical trials. 7. For WOCBP, a serum or urine pregnancy test must be negative at Screening and on the day of study product injection. 8. Must be able to read, understand, and complete questionnaires and diary entries. 9. Plans to reside within study area for the duration of the study. 10. Able to comply with study procedures for the full duration of the study, in the opinion of the investigator. Exclusion Criteria: 1. Known history of COVID-19 or SARS-CoV-2 infection within six (6) months prior to vaccination (Day 1). 2. Receipt of a booster COVID-19 vaccination in addition to the primary vaccine series. 3. Presence of fever >100.4°F/38°C or other signs or symptoms of COVID-19 (e.g., chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea) within 1 week prior to Day 1 study product injection. Screening and/or study product injection may be rescheduled at the discretion of the investigator. 4. Clinical manifestations of systemic diseases considered by the investigator to impact safety or immunogenicity. 5. Prior history of pericarditis or myocarditis of any etiology. 6. Prior history of thrombosis of major vessels, including cerebrovascular or splanchnic thrombosis or of thrombosis with thrombocytopenia syndrome 7. History of anaphylaxis (vaccine related or not). 8. Chronic kidney disease with dialysis. 9. Receipt of systemic corticosteroids (=0.5 mg/kg per day of prednisone or equivalent)for =7 days is prohibited from 28 days before enrollment through conclusion of the study. Topical, inhaled, intra-nasal, intra-articular or intra-bursal administration of corticosteroids is permitted. 10. Receipt of any cytotoxic or immunosuppressive drug or biologics six (6) months prior to Day 1 visit. 11. Receipt of any investigational drug within six (6) months prior to Day 1 visit. 12. Subject received or plans to receive a live attenuated vaccine or licensed adjuvanted(non-aluminum compound) vaccination within 28 days before or after planned administration of study vaccine (Day 1) or another type of vaccine (including influenza vaccine) within 14 days prior to or after planned administration of study vaccine on Day1 visit. 13. Human immunodeficiency virus (HIV) or hepatitis B surface antigen (HBsAg) positive; hepatitis C virus (HCV) antibody positive subjects may be tested for RNA and if negative may be enrolled. 14. Any Grade 2 or greater clinical or laboratory abnormalities at screening results. Grade 1 abnormal clinical or laboratory adverse event screening test results which, according to the investigator, are non-clinically significant would not disqualify a potential subject. Clinical or laboratory screening tests may be repeated once to exclude transient abnormalities. 15. Immunocompromised state (weakened immune system) from solid organ transplant, immunosuppressive or immunodeficient state, autoimmune diseases, asplenia and, recurrent severe infections. 16. Have an active malignancy or history of metastatic or hematologic malignancy except non-melanoma skin cancers. 17. Pregnant or breastfeeding female, or female who intends to become pregnant during the study period. 18. Administration of immunoglobulins and/or any blood products within the 120 days preceding Day 1 or planned administration during the study period. 19. Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. 20. Bilateral tattoos or scars at the deltoid sites of intramuscular (IM) injection that would obscure examination of injection site reactions. 21. Behavioral, cognitive, or psychiatric disease that, in the opinion of the Principal Investigator or his or her representative physician, affects the subject's ability to understand and cooperate with all study protocol requirements. 22. Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has caused medical, professional, or family problems, indicated by clinical history. 23. Grade 2 or higher hypertension (systolic >160 mm Hg and/or diastolic >100 mm Hg). 24. Any other condition that, in the opinion of the Principal Investigator or his/her representative physician, could put the safety/rights of potential subjects at risk or prevent them from complying with the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
UB-612
UB-612 (100µg), 0.5mL suspension, intramuscular injection
BNT162b2 vaccine
BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
ChAdOx1-S vaccine
ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10^10 viral particles, intramuscular injection
Sinopharm BIBP
Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection

Locations

Country Name City State
Panama Cevaxin David David
Panama Cevaxin 24 de Dieciembre Panamá
Panama Cevaxin The Panama Clinic Panamá
Philippines Health Index Multispecialty Bacoor
Philippines Iloilo Doctors Hospital Iloilo City
Philippines St Pauls Hospital Iloilo City Iloilo City
United States PanAmerican Clinical Research Brownsville Texas

Sponsors (3)

Lead Sponsor Collaborator
Vaxxinity, Inc. Coalition for Epidemic Preparedness Innovations, Syneos Health

Countries where clinical trial is conducted

United States,  Panama,  Philippines, 

References & Publications (5)

Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P, Clutterbuck EA, Davies S, Dejnirattisai W, Dold C, Ewer KJ, Folegatti PM, Fowler J, Hill AVS, Kerridge S, Minassian AM, Mongkolsapaya J, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Sheehan E, Smith H, Snape MD, Song R, Woods D, Screaton G, Gilbert SC, Voysey M, Pollard AJ, Lambe T; Oxford COVID Vaccine Trial group. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021 Sep 11;398(10304):981-990. doi: 10.1016/S0140-6736(21)01699-8. Epub 2021 Sep 1. — View Citation

Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines (Basel). 2022 Jan 6;10(1). pii: 86. doi: 10.3390/vaccines10010086. — View Citation

Matthes H, Herbst H, Schuppan D, Stallmach A, Milani S, Stein H, Riecken EO. [Distribution of procollagen transcripts in chronic inflammatory bowel diseases using in situ hybridization]. Verh Dtsch Ges Inn Med. 1991;97:12-7. German. — View Citation

Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020 Jun;26(6):729-734. doi: 10.1016/j.cmi.2020.03.026. Epub 2020 Mar 28. Review. — View Citation

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 29;:. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Ability to boost cellular immunity Cytokine secreting spots per million cells and % cells staining for cytokines measured by ELISpot and ICS Days 1, 15 and 29, and Months 6 and 12
Other Ability to boost humoral immunity (non-neutralizing) Fc-mediated antibody ADCP (antibody dependent cell-mediated phagocytosis) responses Day 1 and Day 29
Other Ability to boost humoral immunity (neutralizing) against additional variant - GMT via neutralizing antibodies Geometric Mean Titers in neutralizing antibody titers measured using additional variant replicating or pseudotyped viruses Day 1 and Day 29
Other Ability to boost humoral immunity (neutralizing) against additional variant - GMR via neutralizing antibodies Geometric Mean Titer Ratios in neutralizing antibody titers measured using additional variant replicating or pseudotyped viruses Day 1 and Day 29
Other Ability to boost humoral immunity (neutralizing) against additional variant - GMFI via neutralizing antibodies Geometric Mean Fold Increase in neutralizing antibody titers measured additional variant replicating or pseudotyped viruses Day 1 and Day 29
Primary Presence of solicited local or systemic reactions Local: pain, tenderness, erythema, induration, pruritis. Systemic: Nausea, diarrhea, headache, fatigue, myalgia, chills, joint pain, rash Day 8 after injection
Primary Presence of unsolicited local or systemic reactions Any AE reported by the subject that is not specified as a solicited Day 29 after injection
Primary Presence of serious adverse events SAE are reported through the study Day 387 after injection
Primary Presence of medically attended adverse events AE that leads to an unscheduled visit Day 387 after injection
Primary Presence of adverse events of special interest AESI are reported throughout the study Day 387 after injection
Primary Boost in neutralizing antibody titers against Wuhan strain at Day 29 Geometric Mean Titer Ratios of neutralizing antibodies at Day 29 determined using replicating or pseudotyped virus Day 29 after injection
Secondary Boost in neutralizing antibody titers against Omicron strain at Day 29 Geometric Mean Titer Ratios of neutralizing antibodies at Day 29 determined using replicating or pseudotyped virus Day 29 after injection
Secondary Responders determined on Day 29 (Wuhan) Proportion of subjects with =4-fold antibody titer rise from Day 1 to Day 29 Day 1 to 29 after injection
Secondary Responders determined on Day 29 (Omicron) Proportion of subjects with =4-fold antibody titer rise from Day 1 to Day 29 Day 1 to 29 after injection
Secondary Kinetics and duration of antibody response - Responders via neutralizing antibodies Proportion of subjects with =4-fold antibody titer rise over the life of trial measured by neutralizing antibodies determined using replicating or pseudotyped virus Day 1 to Day 15, Day 29, and Months 6 and 12
Secondary Kinetics and duration of antibody response - Responders via binding to S1-RBD Proportion of subjects with =4-fold antibody titer rise over the life of trial measured by IgG antibodies titers measured by direct S1-RBD binding ELISA Day 1 to Day 15, Day 29, and Months 6 and 12
Secondary Kinetics and duration of antibody response - GMFI via neutralizing antibodies Geometric Mean Fold Increase of neutralizing antibodies determined using replicating or pseudotyped virus Day 1 to Day 15, Day 29, and Months 6 and 12
Secondary Kinetics and duration of antibody response - GMFI via binding to S1-RBD Geometric Mean Fold Increase of IgG antibodies titers measured by direct S1-RBD binding ELISA Day 1 to Day 15, Day 29, and Months 6 and 12
Secondary Kinetics and duration of antibody response - AUC via neutralizing antibodies Area under the curve (AUC) by treatment group and virus variants calculated from neutralizing antibody response determined using replicating or pseudotyped virus Day 15 to Month 12
Secondary Kinetics and duration of antibody response - AUC via binding to S1-RBD Area under the curve (AUC) by treatment group and virus variants calculated from IgG antibody response measured by direct S1-RBD binding ELISA Day 15 to Month 12
Secondary Kinetics and duration of antibody response - GMT via neutralizing antibodies Geometric Mean Titers measured by neutralizing antibody response by treatment group and virus variants Days 15, 29, and Months 6 and 12
Secondary Kinetics and duration of antibody response - GMT via binding to S1-RBD Geometric Mean Titers measured by IgG antibody response measured by direct S1-RBD binding ELISA Days 15, 29, and Months 6 and 12
Secondary Kinetics and duration of antibody response - Reverse Cumulative Distribution Curve via neutralizing antibodies Distribution of neutralizing antibody titers displayed as reverse cumulative distribution curves by treatment group and virus variants measured by neutralizing antibody response Day 29 and Month 6 and 12
Secondary Kinetics and duration of antibody response - Reverse Cumulative Distribution Curve via binding to S1-RBD Distribution of IgG antibody titers displayed as reverse cumulative distribution curves by the treatment group and virus variant measured IgG antibody response measured by direct S1-RBD binding ELISA Day 29 and Month 6 and 12
See also
  Status Clinical Trial Phase
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Recruiting NCT05185817 - Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients Phase 2
Not yet recruiting NCT04876885 - The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations N/A
Completed NCT05373459 - Effect of a Third COVID-19 Booster Among Health Care Workers
Active, not recruiting NCT05571657 - COVID-19 Booster Dose Reminder/Recall for Adolescents N/A
Completed NCT04888793 - Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Completed NCT04881396 - Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
Recruiting NCT04871165 - Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
Active, not recruiting NCT05405283 - Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults Phase 3
Recruiting NCT05508477 - UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study) Phase 3
Recruiting NCT05471635 - Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
Recruiting NCT06282692 - INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old Phase 3
Completed NCT05406908 - Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases Phase 4
Recruiting NCT04895007 - Comparative Evaluation of Covid-19 Vaccines Response
Recruiting NCT05831826 - Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
Recruiting NCT05096260 - Getting to Yes, Michigan! (G2YMI) N/A
Completed NCT04962906 - Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes Phase 2
Active, not recruiting NCT05027672 - Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. Phase 2

External Links